(2,5-二氧代咪唑啉-1-基)乙酸 | 80258-94-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2,5-二氧代咪唑啉-1-基)乙酸
• 中文别名: (2,5-二氧代-咪唑啉-1-基)-乙酸
• 英文名称: hydantoin-3-acetic acid
• 英文别名: 2-(2,5-dioxoimidazolidin-1-yl)acetic acid；(2,5-dioxoimidazolidin-1-yl)acetic acid
• CAS: 80258-94-2
• 化学式: C₅H₆N₂O₄
• mdl: MFCD02333377
• 分子量: 158.114
• InChiKey: UYBPMPGSEWRTLG-UHFFFAOYSA-N

物化性质

• 熔点：
  190-191 °C
• 密度：
  1.565±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  86.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : (2,5-Dioxoimidazolidin-1-Yl)Acetic Acid
: CBR00560
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 158,12 g/mol
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
No special environmental precautions required.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
No special environmental precautions required.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2,5-二氧代咪唑啉-1-基)乙酸 在 sodium hydroxide 作用下， 生成 N,N'-bis(carboxymethyl)urea
  参考文献：
  名称：

  Graenacher; Landolt, Helvetica Chimica Acta, 1927, vol. 10, p. 808

  摘要：

  DOI：
• 作为产物：
  描述：

  2,5-噁唑烷二酮 在 N,N-二甲基甲酰胺 、 lithium chloride 作用下， 生成 (2,5-二氧代咪唑啉-1-基)乙酸
  参考文献：
  名称：

  Ballard et al., Proceedings of the Royal Society of London, Series A: Mathematical, Physical and Engineering Sciences, 1955, vol. 227, p. 155,164, 165, 172-176

  摘要：

  DOI：

文献信息

• Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents
  作者：William A. Denny、Bruce F. Cain、Graham J. Atwell、Corwin Hansch、Augustine Panthananickal、A. Leo

  DOI：10.1021/jm00345a015

  日期：1982.3

  relationships (QSAR) have been derived between antileukemic (L1210) activity and agent physicochemical properties for 509 tumor-active members of the general class of 9-anilinoacridines. One member of this class is the clinical agent m-AMSA (NSC 249992). Agent hydrophobicity proved a significant but not a dominant influence on in vivo potency. The electronic properties of substituent groups proved important

  已针对9类苯胺基between啶类化合物中的509种肿瘤活性成员，在抗白血病（L1210）活性与药物理化性质之间建立了定量关系（QSAR）。此类药物之一是临床药物m-AMSA（NSC 249992）。试剂疏水性已证明对体内效力有显着但非主要的影响。取代基的电子性质被证明是重要的，但是对药物效力的最显着影响是通过位于9-苯胺基cr啶骨架上不同位置的基团的空间影响显示出来的。这些结果与这些化合物发挥作用的重要生理步骤完全一致，它们是通过在碱基对之间插入idine啶发色团并在小沟中放置苯胺基而将它们与双链DNA结合的，如前所述。还推导了9-苯胺基cr啶的643种衍生物的急性毒性方程。该方程采用与模拟抗白血病药效价相似的形式，强调了抗肿瘤药的药效和急性毒性之间通常相当紧密的关系。这项研究证明了QSAR技术的强大功能，可以构建大量的生物学数据，并允许从中提取有用的信息，这取决于有关化合物的可能作用部
• [EN] BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS<br/>[FR] DÉRIVÉS DE STABILISATION DE BENZOPYRANE ET D'IMIDAZOLE UTILISÉS POUR LA STABILISATION DE CHAÎNES LÉGÈRES D'IMMUNOGLOBULINES AMYLOÏDOGÉNIQUES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2020205683A1

  公开（公告）日：2020-10-08

  In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL patients, such as those with substantial cardiac involvement who have difficulty tolerating existing chemotherapy regimens, provided herein are small molecule compounds of Formula Ia, Formula Ib, and Formula II that are kinetic stabilizers of the native dimeric structure of full-length LCs, which compounds can slow or stop the amyloidogenicity cascade at its origin.

  在免疫球蛋白轻链淀粉样变性（AL）中，每位患者体内由单克隆浆细胞分泌的独特抗体轻链（LC）蛋白会错误折叠和/或聚集，导致器官退化的过程。为了治疗AL患者，例如那些存在严重心脏受累且难以耐受现有化疗方案的患者，本文提供了化学式Ia、化学式Ib和化学式II的小分子化合物，这些化合物是全长LC的动力学稳定剂，可以减缓或停止淀粉样生成性级联反应的起源。
• Systematic Evaluation of the Metabolism and Toxicity of Thiazolidinone and Imidazolidinone Heterocycles
  作者：Shi Qing Tang、Yong Yang Irvin Lee、David Sheela Packiaraj、Han Kiat Ho、Christina Li Lin Chai

  DOI：10.1021/acs.chemrestox.5b00247

  日期：2015.10.19

  The thiazolidine and imidazolidine heterocyclic scaffolds, i.e., the rhodanines, 2,4-thiazolidinediones, 2-thiohydantoins, and hydantoins have been the subject of debate on their suitability as starting points in drug discovery. This attention arose from the wide variety of biological activities exhibited by these scaffolds and their frequent occurrence as hits in screening campaigns. Studies have been conducted to evaluate their value in drug discovery in terms of their biological activity, chemical reactivity, aggregation-based promiscuity, and electronic properties. However, the metabolic profiles and toxicities have not been systematically assessed. In this study, a series of five-membered multiheterocyclic (FMMH) compounds were selected for a systematic evaluation of their metabolic profiles and toxicities on TAMH cells, a metabolically competent rodent liver cell line and HepG2 cells, a model of human hepatocytes. Our studies showed that generally the rhodanines are the most toxic, followed by the thiazolidinediones, thiohydantoins, and hydantoins. However, not all compounds within the family of heterocycles were toxic. In terms of metabolic stability, 5-substituted rhodanines and 5-benzylidene thiohydantoins were found to have short half-lives in the presence of human liver microsomes (t1/2 < 30 min) suggesting that the presence of the endocyclic sulfur and thiocarbonyl group or a combination of C5 benzylidene substituent and thiocarbonyl group in these heterocycles could be recognition motifs for P450 metabolism. However, the stability of these compounds could be improved by installing hydrophilic functional groups. Therefore, the toxicities and metabolic profiles of FMMH derivatives will ultimately depend on the overall chemical entity, and a blanket statement on the effect of the FMMH scaffold on toxicity or metabolic stability cannot and should not be made.

  噻唑烷和咪唑烷杂环骨架，即罗丹宁、2,4-噻唑烷二酮、2-硫代海因和海因，其作为药物发现的起始点的适宜性一直是争论的主题。这种关注源于这些骨架所展现的多样化的生物活性和它们在筛选活动中频繁出现作为命中物。已经进行了研究来评估它们在药物发现中的价值，包括它们的生物活性、化学反应性、基于聚集的杂乱性以及电子性质。然而，它们的代谢轮廓和毒性尚未被系统地评估。在这项研究中，选择了一系列五元多杂环（FMMH）化合物，对它们在TAMH细胞（一种代谢能力健全的啮齿动物肝细胞系）和HepG2细胞（一种人肝细胞模型）上的代谢轮廓和毒性进行了系统评估。我们的研究表明，一般来说，罗丹宁的毒性最大，其次是噻唑烷二酮、硫代海因和海因。然而，并非所有杂环家族中的化合物都具有毒性。在代谢稳定性方面，发现5-取代的罗丹宁和5-苄叉基硫代海因在人肝微粒体存在下具有较短的半衰期（t1/2 < 30分钟），这表明在这些杂环中的环内硫和硫羰基或5位苄叉基取代和硫羰基的组合可能是P450代谢的识别基序。然而，通过引入亲水性功能基团可以提高这些化合物的稳定性。因此，FMMH衍生物的毒性和代谢轮廓最终将取决于整体化学实体，关于FMMH骨架对毒性或代谢稳定性的影响不能也不应该做出笼统的陈述。
• Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives
  作者：Paul G Wyatt、Michael J Allen、Josie Chilcott、Alison Foster、David G Livermore、Jackie E Mordaunt、Jan Scicinski、Patrick M Woollard

  DOI：10.1016/s0960-894x(02)00159-2

  日期：2002.5

  novel, potent and selective oxytocin antagonists are reported. Combinatorial libraries designed to find novel replacements of fragments of oxytocin antagonist L-371,257, identified pyrimidine, thiazole, indole and benzofuran as potential alternatives to the benzoic acid moiety of L-371,257. Additional investigations identified indole and benzofuran derivatives with potent oxytocin antagonist activity

  报道了发现新颖，有效和选择性催产素拮抗剂的研究。设计用于寻找催产素拮抗剂L-371,257片段的新型替代物的组合文库，将嘧啶，噻唑，吲哚和苯并呋喃确定为L-371,257苯甲酸部分的潜在替代物。进一步的研究确定了具有有效催产素拮抗剂活性的吲哚和苯并呋喃衍生物。
• Latent inhibitors. Part 4. Irreversible inhibition of dihydro-orotate dehydrogenase by hydantoins derived from amino acids
  作者：Ian G. Buntain、Colin J. Suckling、Hamish C. S. Wood

  DOI：10.1039/p19880003175

  日期：——

  Hydantoins and ureas derived from α-amino acids are shown to interact with dihydro-orotate dehydrogenase from Clostridium(Zymobacterium)oroticum, chiefly as weak competitive inhibitors but that the hydantoin derived from phenylalanine, 5-benzyl-3-(1-carboxy-2-phenylethyl)hydantoin, is a time-dependent irreversible inhibitor of the enzyme. Inhibition experiments with derivatives of this hydantoin and

  乙内酰脲和从α-氨基酸衍生的脲被示出为与相互作用从二氢乳清酸脱氢酶梭菌（Zymobacterium）oroticum，主要是作为弱竞争性抑制剂，但衍生自苯丙氨酸的乙内酰脲，5-苄基-3-（1-羧基-2-苯基乙基）乙内酰脲是该酶的时间依赖性不可逆抑制剂。用该乙内酰脲的衍生物及其固有的化学反应性进行的抑制实验导致了一种假设的抑制反应机理，该机制涉及乙内酰脲的苄基氧化，然后迈克尔加成酶亲核试剂。通过分子图比较底物和抑制剂的结构，讨论了该反应与正常底物氧化反应之间的关系。